TGTX

TG THERAPEUTICS, INC.

TGTX · CIK 1001316 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$616M
20182025
Net Income$447M
20182025
Operating CF−$25M
20182025
Free Cash Flow−$25M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.6B$0.3B$0.2B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue$0.1B$0.0B$0.0B—————
Gross Profit————————
R&D Expense$0.2B$0.1B$0.1B$0.1B$0.2B$0.2B$0.2B$0.2B
SG&A Expense$0.2B$0.2B$0.1B$0.1B$0.1B———
Operating Income$0.1B$0.0B$0.0B$-0.2B$-0.3B$-0.3B$-0.2B$-0.2B
Net Income$0.4B$0.0B$0.0B$-0.2B$-0.3B$-0.3B$-0.0B$-0.1B
EPS (Basic)$3.10$0.16$0.09$-1.46————
EPS (Diluted)$2.77$0.15$0.09$-1.46————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$1.1B$0.6B$0.3B$0.2B$0.4B$0.6B$0.2B$0.1B
Current Assets$0.6B$0.6B$0.3B$0.2B$0.3B$0.6B$0.1B$0.1B
Cash & Equivalents$0.1B$0.2B$0.1B$0.1B$0.3B$0.6B$0.1B$0.0B
Total Liabilities$0.4B$0.4B$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B
Current Liabilities$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B
Stockholders' Equity$0.6B$0.2B$0.2B—————

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.2B$-0.3B$-0.2B$-0.1B—
Investing Cash Flow$0.0B$-0.0B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B—
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.1B$0.1B$0.1B$-0.0B$0.0B$0.7B$0.2B—
← Companies